CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.
Mendelsohn J, Prewett M, Rockwell P, Goldstein NI. CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth. Clin Cancer Res. 2015 Jan 15; 21(2):227-9.